Catalyst Biosciences PE Ratio 2006-2021 | CBIO

Current and historical p/e ratio for Catalyst Biosciences (CBIO) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Catalyst Biosciences PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Catalyst Biosciences PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 3.47 0.00
2021-06-30 4.33 $-3.02 0.00
2021-03-31 5.04 $-3.34 0.00
2020-12-31 6.31 $-2.83 0.00
2020-09-30 4.30 $-3.20 0.00
2020-06-30 5.87 $-3.53 0.00
2020-03-31 4.37 $-3.72 0.00
2019-12-31 6.81 $-4.70 0.00
2019-09-30 4.91 $-4.38 0.00
2019-06-30 7.37 $-3.96 0.00
2019-03-31 8.11 $-3.35 0.00
2018-12-31 7.89 $-2.65 0.00
2018-09-30 10.78 $-2.70 0.00
2018-06-30 11.67 $-3.40 0.00
2018-03-31 25.80 $-5.39 0.00
2017-12-31 13.64 $-9.40 0.00
2017-09-30 5.06 $-13.12 0.00
2017-06-30 4.65 $-17.78 0.00
2017-03-31 9.43 $-21.54 0.00
2016-12-31 9.75 $-21.62 0.00
2016-09-30 18.15 $-16.94 0.00
2016-06-30 22.80 $-10.94 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.109B $0.021B
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76